Beam Therapeutics reports BEAM-302 data, plans FDA accelerated approval pathway
AI Summary- Beam Therapeutics presented updated Phase 1/2 results for its BEAM-302 AATD therapy.
- 60 mg produced AAT above 11 µM, while mutant Z-AAT fell 84%.
- Beam began dosing a pivotal global cohort in July and plans FDA accelerated approval.